文献速递痛风与晶体性关节病血管炎

痛风及基线血尿酸水平与心血管结局的关联:冠状动脉疾病队列研究分析

Associations of Gout and Baseline Serum Urate Level With Cardiovascular Outcomes: Analysis of the Coronary Disease Cohort Study.
PubMed 文献 · Arthritis Rheumatol · 2019-08-29

该研究基于冠状动脉疾病队列研究,纳入1,514例急性冠脉综合征(ACS)患者,评估痛风及血清尿酸(SU)水平与死亡、心血管事件再入院及心力衰竭的关系。结果显示,痛风患者与非痛风患者ACS后生存率相似,但痛风患者因心力衰竭再入院的风险更高(调整后HR 1.42,95%CI 1.02-1.97),且无论有无痛风,SU水平升高均与死亡及再入院风险增加平行相关。

要点

  • 痛风患者ACS后全因死亡风险与非痛风患者无显著差异(调整后HR 0.98,95%CI 0.69-1.38)。
  • 痛风患者因心力衰竭再入院的时间显著更短(调整后HR 1.42,95%CI 1.02-1.97)。
  • 无论有无痛风,SU水平升高均与死亡及心血管事件或心衰再入院风险增加相关。

核心结论

  • ACS后痛风患者与非痛风患者生存率相似,但痛风患者心衰再入院风险更高且住院时间更长。
  • 无论是否患有痛风,SU水平升高均与死亡及再入院风险增加平行相关。

研究设计与样本

  • 冠状动脉疾病队列研究,纳入因急性冠脉综合征(ACS)入院的患者。
  • 从索引住院病历收集临床数据,出院后收集临床、超声心动图和生化数据。
  • 痛风定义基于自我报告、降尿酸治疗使用或秋水仙碱使用且病历审查有痛风证据。
  • 主要终点为全因死亡、心脏缺血事件再入院时间及心力衰竭再入院时间。
  • 共1,514例参与者数据可用。

主要发现

  • 随访期间,160例痛风患者中53例(33.1%)死亡,1,354例非痛风患者中298例(22.0%)死亡。
  • 调整其他死亡相关因素后,痛风未增加死亡风险(调整后HR 0.98,95%CI 0.69-1.38)。
  • 痛风患者因心力衰竭再入院时间显著更短(调整后HR 1.42,95%CI 1.02-1.97)。
  • 无论有无痛风,SU水平升高均与死亡及心血管事件或心衰再入院风险增加相关。

临床怎么用

  • 对ACS后痛风患者应关注心力衰竭再入院风险,加强心衰监测与管理。
  • SU水平可作为ACS后患者死亡及再入院风险的评估指标,无论是否诊断痛风。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether gout and serum urate (SU) levels are associated with increased risk of death, time to first readmission for any cardiovascular event, or incident heart failure in individuals with cardiovascular disease. METHODS: Individuals presenting with an acute coronary syndrome (ACS) were enrolled in the Coronary Disease Cohort Study. Clinical data were collected from the medical records at the index hospital admission, and clinical, echocardiographic, and biochemical data were collected postdischarge. Gout was defined by self-report, use of urate-lowering therapy, or use of colchicine with evidence of gout on review of the medical record. The primary end points were all-cause mortality, time to readmission for a cardiac ischemic event, and time to readmission for heart failure. RESULTS: Data from 1,514 participants were available. During the follow-up period, 53 of 160 participants with gout (33.1%) and 298 of 1,354 participants without gout (22.0%) died. After adjustment for other factors known to be associated with mortality, there was no gout-specific increase in risk of mortality (adjusted hazard ratio 0.98 [95% confidence interval 0.69-1.38]). Time to readmission for heart failure was significantly briefer in those with, compared to those without, gout (adjusted hazard ratio 1.42 [95% confidence interval 1.02-1.97]). Irrespective of whether a participant had gout or not, as SU level increased, there was an increased risk of death and readmission for either a cardiovascular event or heart failure. CONCLUSION: Survival post-ACS is similar with and without the presence of gout. People with gout are at an increased risk of readmission for heart failure and have longer hospital stays. Risk of these events increases in parallel with increases in SU levels.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Stamp LK, Frampton C, Drake J, et al. Associations of Gout and Baseline Serum Urate Level With Cardiovascular Outcomes: Analysis of the Coronary Disease Cohort Study. Arthritis Rheumatol. 2019. PMID: 31162825. doi:10.1002/art.41007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。